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Summary The aim of this study was to test the effectiveness of a regimen of combination chemotherapy
known to be active in advanced breast cancer when given as an adjuvant treatment after mastectomy. A total
of 569 patients with cancer of the breast and involvement of axillary lymph nodes were randomised, after
simple mastectomy with axillary sampling, to receive either no adjuvant treatment or intravenous adriamycin
50mg, vincristine 1 mg, cyclophosphamide 250 mg, methotrexate 150mg and fluorouracil 250mg (AVCMF)
every 21 days for eight cycles. Randomisation was stratified according to menopausal status and tumour size.
Treatment was started within 14 days of surgery in 94% of patients. Eighty-eight per cent of patients received
at least seven cycles of chemotherapy with no dose reduction. The median relapse-free survival was prolonged
by 14 months in patients treated with AVCMF (X2 = 11.7; P = 0.0006). In the premenopausal group this
period was 17 months (x2, = 8.8; P=0.003) compared with 8 months in the post-menopausal group (x2,=3.3;
P=0.07). Neither overall survival nor survival in these subgroups was significantly influenced by treatment.
When given as treatment for advanced cancer of the breast,
combination chemotherapy results in complete or partial
remissions in more than 50% of patients. At this time the
tumour burden is usually large and the patients often
debilitated. Experimients with transplantable tumours in
animals indicate that the potential for cure using
chemotherapy is inversely proportional to the tumour burden
(Skipper, 1978). This led to the concept of administration of
chemotherapy as an adjuvant to surgery, after mastectomy,
when the tumour burden is at its lowest and the patient fit.
Other possible advantages of this approach are that small
tumours are likely to be well vascularised and theoretically
less likely to have become spontaneously resistant to
chemotherapy (Goldie & Coldman, 1979).
In terms of response, combinations of drugs are more
effective for the treatment of advanced breast cancer than
single agents. The first trial of adjuvant combination
chemotherapy was performed in Milan using cyclophos-
phamide, methotrexate and fluorouracil (Bonadonna et al.,
1976). The early results of this study showed a highly
significant reduction in the time to first relapse, particularly
in premenopausal women, and led us to set up the trial
reported here.
The aim of this study was to confirm the Milan results and
to attempt to improve on them. We, therefore, chose to use a
combination of drugs which included adriamycin as the most
active single agent in breast cancer; to use a combination
known to be effective in the treatment of advanced breast
cancer (Price et al., 1983) and to administer the drugs in the
adjuvant situation without reduction of the dose. Also we
wished to begin injections as soon as possible after mastec-
tomy in view of the results of a trial conducted by Nissen-
Meyer et al. (1978), which suggested an advantage for early
treatment.
The trial was started in December 1976 as a multicentre
study within the West Midlands region of the United King-
dom. Preliminary analyses of the study were reported when
the median follow-up times were 22, 54 and 60 months
(Morrison et al., 1981, 1984, 1987). This paper presents a
more complete analysis of the trial 10 years after recruitment
began when the median follow-up was 7 years.
Patients and methods
Selection ofpatients
Patients were entered into the trial by 40 consultant surgeons
from 26 hospitals within the West Midlands Region between
December 1976 and August 1984. Patients with involved
axillary lymph nodes, Tla-T3a tumours and below the age of
65 were eligible. Additional eligibility criteria were:
WBC >4.0 x 1091- 1', platelet count > 100 x 1091- 1', normal
liver function tests, not pregnant or lactating, no previous
malignancy except rodent ulcer, squamous cell carcinoma of
skin or carcinoma in situ of cervix, no serious intercurrent
disease or psychiatric disorder and ability to be followed up
adequately. Mandatory initial investigations were full blood
count, biochemical profile, liver function tests, ECG, chest
and skeletal radiographs and a radioisotope bone scan.
Treatment
Following histological confirmation of the diagnosis all
patients had a simple mastectomy with axillary node samp-
ling (Forrest et al., 1976). Postoperative radiotherapy was not
given. After confirmation of involvement of axillary nodes,
patients were randomised by telephone call to the West
Midlands Cancer Registry and after September 1983 to the
West Midlands Cancer Research Campaign Clinical Trials
Unit to receive either no further treatment or chemotherapy.
Prospective stratification was made for menopausal status
and tumour size. Chemotherapy was started within 7 days of
surgery in 67% and within 14 days in 94% of patients.
Patients were admitted overnight to hospital for subsequent
courses which were given every 21 days for a further seven
cycles. Patients received adriamycin 50 mg i.v. and vincristine
I mg i.v. at 0 h; 6 h later a bolus injection of cyclophos-
phamide (250 mg) was given and a 12 h infusion of 150 mg
of methotrexate started; 5-fluouracil 250 mg and 15 mg of
folinic acid was given i.v. at the end of the infusion. Folinic
acid was given orally (15 mg) on a further three occasions at
6-h intervals. Courses were delayed if there was evidence of
significant myelosuppression (WBC <3 x 1091-; platelets
<100 x 1091- 1') or other serious toxic manifestations. There
were no dosage reductions. Treatment after relapse was
decided by clinicians individually.
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Assessment
Patients were examined every 3 months for 18 months and
thereafter at 6 monthly intervals until recurrence or death. A
full blood count, biochemical profile and liver function tests
were performed at each visit. Chest and skeletal X-rays and
bone scans were performed 6-monthly for 2 years followed
by annual investigations until 5 years. Toxicity was recorded
for each treatment cycle. Nausea and vomiting were graded
as mild or severe on a subjective basis by each surgical team.
Clinicians were also asked to report the duration of major
symptoms in days.
Pathology and receptors
Histology was reviewed centrally by one of us (R.A.W.) and
classified according to histological type and grade; the
grading used (Elston et al., 1982) was a modification of the
system developed by Bloom and Richardson (1957). Oest-
rogen and progesterone receptors were assayed using the
dextran coated charcoal method and Scatchard analysis
(McGuire & De La Garza, 1973). Receptors were taken to be
present if > 5 fmol mg -' cytosol protein were detectable.
Audit
All recurrences were verified histologically if superficial, or by
radiology and scanning if not, and reviewed by one of us
(J.M.M.). External audit was performed by Dr T.J. Powles in
November 1985. Computer files, trial forms, clinical notes
and X-rays were examined for every twentieth patient and
for a random sample of patients with recurrence in bone and
lung.
Statistical analyses
The major end-points of the trial were histologically or
radiologically defined recurrence, and death. The com-
pleteness of the notification of death was verified by registra-
tion of all patients with the West Midlands Regional Cancer
Registry, Birmingham and the National Health Service Cen-
tral Register, Southport. In accordance with accepted statis-
tical practice, this permitted all randomised patients to be
included in the survival analysis (Peto et al., 1977). However,
since there was no notification by clinicians of disease status
for patients who were randomised but were found subse-
quently to be ineligible, only eligible patients are included in
the analysis of recurrence, relapse-free survival and toxicity.
Relapse-free survival and overall survival curves were drawn
using the method of Kaplan and Meier (1958) and the
significance of the differences between curves assessed using
the log rank test (Peto et al., 1977). Treatment comparisons
were stratified by menopausal status and tumour size. In
addition the effect of controlling for menopausal status,
tumour size, age, tumour grade and receptor content was
determined using Cox's multiple regression analysis (Cox,
1972). The reduction in the odds of relapse and death (Early
Breast Cancer Trialists' Collaborative Group, 1988) and
relative improvements were calculated. Patients with uncer-
tain menopausal status (e.g. previous hysterectomy) were
taken to be premenopausal if less than 50 years of age and
post-menopausal if 50 years or older. Patients were taken to
be post-menopausal if they had had no periods within the
previous 6 months.
Results
Patients analysed
A total of 569 patients were randomised (294 treated and 275
control), of whom 540 (277 treated and 263 control) were
eligible according to the criteria given above. Data were
censored at 31 December 1986 when the median follow up
was 7 years. Analysis of survival includes all randomised
patients. However, the other analyses are based on only 539
patients. One treated patient cannot be included because she
was completely lost to follow-up. Twenty-nine patients were
found, on review (K.A.K.), to be ineligible (17 treated and 12
control) and are excluded since they were not followed up.
Patients were excluded after randomisation for the following
reasons; advanced disease (six treated, three control), >65
years of age (four treated, one control), abnormal liver func-
tion tests (one treated, seven control), intercurrent disease
(three treated), node negative (two treated, one control) and
lymphoma (one treated). The characteristics of the patients
eligible for analysis of relapse and toxicity are given in Table
I, which shows that there are no major imbalances of prog-
nostic factors between the treated and control groups.
Relapse-free survival
Adjuvant chemotherapy significantly prolonged relapse free
survival (Figure 1, Table II). After stratification for
menopausal status and tumour size, X21 is 11.9 (P = 0.0006).
Controlling for menopausal status, tumour size, age, tumour
grade or receptor status does not substantially alter this
treatment effect.
The percentage relapse free at 5 years is improved by
treatment from 27% to 38% (with confidence intervals of
21-33% and 32-44% respectively) and represents a relative
improvement (RI) of 42% ((38-27)/27) in relapse rate or a
30% reduction in the odds of relapse (OR). The median
prolongation of relapse free survival is 14 months, from 628
days to 1,057 days (with confidence intervals of 554-808
days and 836-1,290 days respectively).
There were 181 (66%) patients who recurred in the treated
group and 199 (76%) in the control group. There was no
significant difference in the distribution of metastases
between the treatment and control groups (X21 = 0.18;
P= 0.67; Table III).
Table I Patient characteristics
Treated (277patients) Control (263 patients)
n % n %
Age
Less than 50 116 42 115 44
50 plus 161 58 148 56
Menopausal status
Premenopausal 118 43 115 44
Post-menopausal 130 47 117 44
Hysterectomy 29 10 31 12
Tumour size
<2.0 cm 27 10 18 7
2.0-4.9 cm 162 58 170 65
> 5.0 cm 88 32 74 28
Not known - - 1 <1
Histology
Infiltrating duct 221 80 222 84
Infiltrating lobular 33 12 29 11
Other 11 4 4 2
Not reviewed 12 4 8 3
Grade
I 29 11 27 10
II 153 55 156 59
III 81 29 68 26
Not reviewed 14 5 12 5
Oestrogen receptors
Negative 49 18 58 22
Positive 130 47 137 52
Not assayed 98 35 68 26
Progesterone receptors
Negative 54 19 65 25
Positive 88 32 90 34
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Figure 1 Relapse-free survival for all eligible patients. AVCMF
(181/276 relapsed; control (199/263 relapsed); X2, = 11.68;
P= 0.006.
Prolongation of relapse-free survival was highly significant
in premenopausal patients (X2i = 8.8; P = 0.003: Figure 2a)
but of only borderline significance in post-menopausal
patients (X21 = 3.3; P = 0.07: Figure 2b). The relative im-
provement in 5-year relapse rate was 73% in the
premenopausal group (OR = 37%) and 17% (OR = 22%) in
the post-menopausal group. The median prolongation of
relapse free survival was 17 months (from 594 to 1,112 days)
in the premenopausal group and 8 months (from 741 to 978
days) in the post-menopausal group.
Survival
There was no significant effect of chemotherapy on overall
survival (Figure 3), with an RI of 6% and an OR of 9%.
After stratification for menopausal status and tumour size,
x2
= 1.27; P= 0.26. There was no effect of treatment on
survival in any sub-group (Table II). Controlling for
menopausal status, tumour size, age, tumour grade and
receptor status does not alter this result.
Steroid hormone receptors
Measurements ofoestrogen receptor (ER) were performed on
69% (374/540) of tumours and of progesterone receptor (PR)
on 55% (297/540) of tumours (Table I). Seventy-one per cent
of tumours were ER positive and 60% PR positive
(>5 fmol mg-' cytosol protein). There were no significant
differences in patient characteristics between those with and
without receptor measurements. When all patients were
analysed, there was significant prolongation of relapse-free
survival in patients with ER positive (RI = 44%; OR = 28%)
and ER negative tumours (RI = 47%; OR = 37%) (Table II).
There was a highly significant prolongation of relapse-free
survival in patients with PR positive tumours (RI = 68%;
OR= 41%; X2i= 7.8; P=0.005); the effect in patients with
PR negative tumours just failed to reach significance,
(RI = 68%; OR = 32% X21 = 3.4; P = 0.06), but the numbers
in this group were smaller. There was no relationship
between receptor status and overall survival for any group
(Table II).
Relapse-free survival and receptor results in relation to the
menopause are shown in Table IV. The numbers in these
subgroups are small and the results must be viewed with
caution. The greatest relative improvement of 117%
(OR = 48%), accompanied by the longest absolute prolonga-
tion of median relapse-free survival was in the
premenopausal PR positive subgroup (treated group 55
months vs control group 19 months; X21 = 6.2; P = 0.01). In
the post-menopausal group, treated patients with PR
negative tumours fared better, although this result failed to
reach formal levels of significance. None of the subgroups
analysed had a significantly prolonged survival in treated
patients.
Histological grade
Histological grade was assessed on the tumours from all but
14 of the treated patients and all but 12 of the controls. Of
those assessed, 11% were grade I, 60% were grade II and
29% were grade III. There was no difference in the distribu-
tion of grades between the treated and control groups (Table
I). Chemotherapy reduced the risk of relapse in all grades;
Table II Effect of treatment in subgroups of patients
Relapse-free survival Overall survival
Treated Control Treated Control
N R N R x2 p RI OR N D N D X2 p RI OR
Overall 276 181 263 199 11.7 <0.001 42 30 294 143 275 140 0.6 0.45 6 9
Menopausal status
Pre 128 78 126 95 8.8 0.003 73 37 131 59 130 64 0.5 0.49 8 12
Post 148 103 137 104 3.3 0.07 17 22 159 80 142 75 0.5 0.46 8 11
Age
< 50 116 71 115 88 8.1 0.004 69 37 119 54 119 61 0.8 0.37 12 16
>50 160 110 148 111 4.2 0.04 27 24 175 89 156 79 0.1 0.83 1 3
Tumour size
< 5 cm 189 118 188 138 9.3 0.002 42 32 195 85 194 94 1.5 0.23 12 17
> 5 cm 87 63 74 60 3.0 0.08 45 27 92 53 77 44 0.0 0.94 0 2
ER status
Positive 130 84 137 102 4.8 0.03 44 28 130 54 137 61 0.3 0.60 6 9
Negative 49 35 58 50 4.4 0.04 47 37 49 36 58 40 0.0 0.88 -14 -4
PR status
Positive 88 50 90 67 7.8 0.005 68 41 88 32 90 38 0.7 0.40 9 18
Negative 54 38 65 52 3.4 0.06 68 32 54 31 65 38 0.1 0.80 10 6
Grade
I 29 10 27 18 7.3 0.007 74 65 29 6 27 8 0.83 0.36 5 39
II 153 106 156 121 4.4 0.04 37 24 153 71 156 74 0.09 0.77 6 5
III 80 55 68 53 3.5 0.06 46 31 81 48 68 45 1.0 0.33 10 18
N, numberofpatients in subgroup; R, numberofpatients who have relapsed; D, number ofpatientswho havedied; RR, relative risk reduction in
treated group; OR, odds reduction in treated group.
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Table III Sites of first recurrence
Treated (181) Control (199)
n (%W) n (%W)
Local and regional recurrence only 87 (49) 92 (47)
Distant recurrence 91 (51) 105 (53)
Site of distant recurrences
Bone 36 (20) 46 (23)
Liver 9 (5) 8 (4)
Lung 26 (15) 25 (13)
Otherb 13 (7) 12 (6)
Distant and local recurrence 7 (4) 14 (7)
Site not reviewed'
3 2
b~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1% of those reviewed. bAscites (2C), brain (5T, 2C), contralateral
breast (6T, SC), contralateral axilla (IT, 2C), contralateral nodes and
axilla (IT, IC). cDied with disease, recurrence not recorded (2T, IC),
notes lost (IT, IC).
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this effect appeared greater in patients with grade I tumours
(RI = 74%; OR = 65%) than in those with grade II
(RI = 37%; OR = 24%) or grade III (RI = 46%; OR = 31%;
Table II). The relationship between grade and relapse-free
survival was analysed according to menopausal status (Table
V). Because of the relatively low numbers of grade I
tumours, grades I and II were combined. The greatest pro-
longation of relapse-free survival was seen in premenopausal
women with grade I/II tumours (median 63 months vs 24
months; RI = 97%; OR = 43%; P = 0.004). The effect of
AVCMF on relapse-free survival was not significant for
premenopausal women with grade III tumours or in either
post-menopausal group.
Chemotherapy
Eighty per cent of eligible patients in the treatment group
received eight cycles of treatment, 88% seven cycles or more
and 91% four cycles or more; 3% of eligible patients ran-
6 7 9 10
33 22 22 22 22
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At risk Time (years)
AVCMF 148 120 88 68 50 41 30 30 14 3 3
Control 137 96 68 55 37 33 18 12 8 8 8
Figure 2 Relapse-free survival by menopausal status for eligible patients. a, Premenopausal patients: AVCMF (78/128 relapsed);
control (95/126 relapsed); X2, = 8.75; P = 0.003. b, Post-menopausal patients: AVCMF (103/148 relapsed; control (104/137
relapsed); X21 = 3.26; P = 0.07.
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Figure 3 Survival for all randomised patients. AVCMF (144/294
died); control (140/275 died); X2, = 0.50; P = 0.48.
domised to treatment received no chemotherapy. The reasons
for not receiving the full course of eight cycles of
chemotherapy were toxicity (22%), intercurrent illness not
associated with treatment (15%), patient refusal (37%) and
administrative errors mainly involving failure to give the
eighth cycle (26%).
Toxicity
The proportion of patients affected and the number of cycles
in which toxic effects were seen are summarised in Table VI.
Severe leukopenia and thrombocytopenia were rare. Most
patients had nausea and vomiting on at least one occasion.
When these symptoms were analysed on a per cycle basis,
66% of cycles were associated with nausea and 47% with
vomiting. Treatment was delayed by one week in 74 cycles
and longer in 39. Alopecia was virtually universal but other
side-effects such as stomatitis or neuropathy were uncom-
u
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Table IV Effect of treatment on RFI by menopausal and receptor status
Median % RF at
N R RFI 5 years RI OR X21 p
Premenopausal kK positive
Treated 58 34 1092 42 63 32 2.8 0.10
Control 54 39 771 26
Premenopausal ER negative
Treated 28 20 645 35 77 42 3.4 0.07
Control 30 27 411 20
Premenopausal PR positive
Treated 55 31 1677 49 117 48 6.2 0.01
Control 43 33 582 22
Premenopausal PR negative
Treated 16 12 467 21 12 10 0.1 0.77
Control 25 21 411 19
Post-menopausal ER positive
Treated 72 50 1158 36 28 22 1.8 0.18
Control 83 63 619 28
Post-menopausal ER negative
Treated 21 15 734 29 1 27 0.9 0.34
Control 28 23 554 28
Post-menopausal PR positive
Treated 33 19 1155 37 19 31 1.8 0.18
Control 47 34 741 31
Post-menopausal PR negative
Treated 38 26 946 41 56 39 3.3 0.07
Control 40 31 497 26
N, numberofpatients in subgroup; R, numberofpatients who have relapsed; RR, relative risk reduction
in treated group; OR, odds reduction in treated groups.
Table V Effect of treatment on RFI by menopausal status and grade
Median % RF at
N R RFI 5 years RR x2 p
Grade I/II
Treated 182 116 1238 41 46 8.7 0.003
Control 183 139 741 28
Grade III
Treated 80 55 775 33 46 3.5 0.06
Control 68 53 482 23
Premenopausal grade 1/IT
Treated 77 43 1915 52 97 8.5 0.004
Control 86 65 724 26
Premenopausal grade III
Treated 42 29 638 32 74 2.3 0.13
Control 32 26 482 18
Post-menopausal grade I/II
Treated 105 73 987 33 16 1.7 0.19
Control 97 74 741 29
Post-menopausal grade III
Treated 38 26 887 35 32 1.3 0.25
Control 36 27 456 27
N, number of patients in subgroup; R, number of patients who have relapsed; RR,
relative risk reduction in treated group.
mon. In particular, there were no episodes of cardiac failure. had toxicity. Patients we
The severity and duration of nausea and vomiting are of cycles patients took t
outlined in Figure 4. Severe symptoms were uncommon. confined to bed for a v
However, when symptoms occurred, they lasted for longer
than 24h in approximately half the cycles assessed. An
assessment of the 'quality of life' of patients is shown in
Figure 4. Patients were asked how long they were unwell, Second primary tumoui
how long they were unable to go to work (or perform (cervix, rectum) and thre
housework) and how long they were confined to bed if they oesophagus). No leukae
ere unwell in 58% of cycles. In 37%
time off work and in 30% they were
variable period.
irs occurred in two of the control
ee of the treated group (cervix, lung,
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Table VI Toxicity attributed to chemotherapy
Patientsa Cycles
Haematology n (253) % n (1651) %
Hb (gdl-')
9.5-10.9 28 11 75 5
<9.5 6 2 6 <1
WBC count (xl10l-')
3-3.9 99 39 233 14
2-2.9 5 2 5 <1
<2 1 <1 1 <1
Platelets (x 109l-')
70-99 2 < 1 2 <1
<70 1 <1 1 <1
Side-effects n (251) % n (1845) %
Nausea 238 95 1224 66
Vomiting 210 84 875 47
Rash 36 14 60 3
Stomatitis 62 25 91 5
Diarrhoea 63 25 130 7
Neuropathy 60 24 95 5
Hair loss 244 97 - -
Cardiac failure 0 0
aRecorded if the toxic event occurred on at least one occasion on at
least oneoccasionperpatient. bNumberoftreatmentcyclesinwhich the
toxic event occurred.
Discussion
This study shows that administration of eight cycles of
AVCMF after mastectomy to women with axillary node
involvement delays local and distant relapse by a median of
14 months. This difference in relapse-free survival has not
been translated into an equivalent advantage in overall sur-
vival. It was hoped that the addition of adriamycin and
vincristine to CMF would enhance the therapeutic effect; our
results do not show a greater effect at this stage of follow-up
compared with CMF trials. At a median follow-up of 7
years, 50% of patients have died. These deaths are in women
who presumably had undetected but extensive micrometa-
static disease present at mastectomy and who would
therefore be expected to recur early after surgery. It remains
to be seen whether the more intensive chemotherapy reported
here will affect survival in patients presumed to have a small
micrometastatic burden at mastectomy. This group would be
expected to have a later recurrence and death and possibly be
the very patients to benefit from adjuvant chemotherapy.
In this study not all patients randomised to treatment
received chemotherapy; eleven ineligible patients (3.7%) may
not have had chemotherapy and eight patients (2.7%),
although eligible, did not receive any treatment, usually due
to patient refusal. Analysis of survival with or without these
groups does not alter the result.
The median prolongation of the time to relapse was 14
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months for all patients: 17 months in the premenopausal
group and 8 months in the post-menopausal group. It is
clearly difficult to make judgements concerning the trade off
in cost related to the toxicity and inconvenience of
chemotherapy and benefit related to the increased period free
from recurrence of disease. The treatment was relatively
myelosuppressive but there were no infective or other toxic
deaths. There were no episodes of cardiac failure, although
the total dose of adriamycin (400 mg) was well below that
which can produce cardiotoxicity and the trial was confined
to patients below age 65 because of this potential risk. Just
over half of the cycles of chemotherapy were associated with
symptoms of toxicity and in half of these, the symptoms
lasted for more than 24 h. Thus, in chemotherapy term, this
regimen of treatment is relatively non-toxic.
The significance ofA VCMF in relation to other trials
The results of our trial must be set in the context of the Early
Breast Cancer Trialists' Collaborative Group (1988) 'over-
view' of all trials of combination chemotherapy with a no
treatment control arm. In the overview, trials of combination
chemotherapy were divided into three groups: CMF
regimens, CMF regimens with extra cytotoxic agents and
regimens without some or all of C, M, F.
The trial reported here falls into the group of CMF
regimens with extra cytotoxic agents. It is the only study in
the group with more than 150 patients randomised, where
the data are available and where there is adequate follow-up.
Patients from this trial represent 39% (569/1,467) of those
analysed in this group. The results from this trial are consis-
tent with the overview for this group which shows a highly
significant improvement in relapse-free survival and a clear
survival advantage in young women, but no clear survival
advantage in older women. The overview shows a reduction
in the odds of relapse of 30% both for this group and for all
polychemotherapy trials; in this analysis the odds reduction
is also 30%. The reduction in the odds of death of 26% in
young women shown for our trial in the overview is similar
to the average reduction of 20% for all trials in this group
and the same as the overall average for all polychemotherapy
trials of 26%. With a median of 7 years follow-up the odds
reduction is now 16%.
This regimen, with a reduction in the odds of death of
26% in the overview, appears to be intermediate in
effectiveness between CMF (OR = 37%) and other multiple
agents (OR = 12%), and is very close to the overall average
improvement of 26% reported for all polychemotherapy
trials and 22% for all chemotherapy trials. Care must be
taken when comparing groups of chemotherapies. The over-
view shows no significant heterogeneity between the
chemotherapy trials reported, so that such comparisons
between groups of chemotherapies must be regarded as
useful for the generation of hypotheses, rather than being
definitive.
Steroid hormone receptors
ER and PR were measured on 69% and 55% of tumours.
Analysis showed no significant relationship between ER and
relapse-free survival and overall survival whereas there was a
significant effect of chemotherapy upon relapse-free survival
but not overall survival in patients with PR positive tumours
(Table II). This appeared to be mainly in the premenopausal
group (Table IV) but the numbers in the subsets were small
and must be viewed with caution. However, although not
reliable in its own right, the result is consistent with most
other trials where this has been examined since most show a
significant advantage for treatment for relapse-free survival
and overall survival in premenopausal women with receptor
positive tumours (Table VII). Most trials show a positive
association between the effectiveness of chemotherapy and
the induction of amenorrhoea. Taken together the relation-
ship between ovarian suppression and receptors with the
effect of chemotherapy suggests that it is acting, in part, by
an indirect endocrine effect.
TableVII Effect ofchemotherapy inrelation toinduced amenorrhoea
and steroid receptors
Trial Amenorrhoea Receptors
Relapse-free survival
Milan CMF NS
(Bonadonna et al., 1985)
Guys/Manchester CMF + + (PR)
(Howell et al., 1984; Padmanabhan et al., 1986)
Denmark
0 C + + (ER)
(Brinckler et al., 1987)
CMF NS NS (ER)
Leiden CMF NS
(Repelaer van Driel et al., 1986)
Nijmegan CMF + + (PR)
(Beex et al., 1988)
Ludwig CNF±p + + (ER)
(Ludwig Breast Cancer Study Group, 1985)
ECOG CMF±P + + (ER)
(Tormey, 1984)
West Midlands AVCMF + (PR)
Survival
Milan CMF NS
Guys/Manchester CMF + + (PR)
Nijmegan CMF + + (PR)
ECOG CMF±p + + (PR)
West Midlands AVCMF NS (PR)
NS, not significant; +, positive effect; -, not reported
Histological grade
We have shown that AVCMF is most active in prolonging
relapse-free survival in premenopausal women with grade I
and II tumours. These tumours are more likely to be steroid
hormone receptor positive compared with grade III tumours.
This supports the association in this study between PR
positive tumours and prolonged relapse free survival and is
consistent with a partial endocrine effect of chemotherapy.
However, there was also an effect in grade III tumours
overall but this failed to reach conventional significance levels
(P = 0.06). These results are not consistent with other
studies. Fisher et al. (1986) reported that melphalan was
active only in women with grade III tumours. Brinckler et al.
(1987) showed that CMF was equally active in women with
grade II and grade III tumours, but was inactive in women
with grade I tumours. It is not clear why the results of the
three studies should be as divergent: it is likely that it is an
effect of small numbers and the subjectiveness of grading.
The latter was standardised in this report by having a single
pathologist look at all the slides.
Conclusion
Taken in isolation the results presented here would not give a
clear indication for the general use of adjuvant chemotherapy
in node positive breast cancer. A useful prolongation of
relapse-free survival was seen in premenopausal women, but
that seen in post-menopausal women was approximately
equivalent to the duration of treatment with chemotherapy
after surgery. It will be important to determine whether this
high risk group of young women fare better when given
adjuvant chemotherapy compared with adjuvant endocrine
therapy: there is clearly a need for clinical trials to compare918 J.M. MORRISON et al.
the effects of each treatment. However, greater improvements
in survival will only come with improved chemotherapy or
the introduction of entirely new treatments. The effectiveness
of adjuvant chemotherapy might be improved by increasing
the intensity of treatment, possibly with haemopoietic growth
factors, by giving treatment early, possibly even before
surgery and by developing new agents. It is in our view
preferable to examine these important factors in well planned
clinical trials than to recommend prematurely the use of
adjuvant chemotherapy in routine clinical practice, partic-
ularly in post-menopausal women.
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